000			03700cam a22005055i 4500
001			21682770
003			ugUCULIB
005			20251103130807.0
006			m |o d |
007			cr |||||||||||
008			150302s2015 ne |||| o |||| 0|eng
010			_a 2019749002
020			_a9789401797320
024	7		_a10.1007/978-94-017-9732-0 _2doi
035			_a21682770
035			_a(DE-He213)978-94-017-9732-0
040			_aDLC _beng _epn _cUCULIB _dUCULIB
072		7	_aMED062000 _2bisacsh
072		7	_aMJCL _2bicssc
072		7	_aMJCL _2thema
082	0	4	_a614.5999 _223 _bKIN
245	0	0	_aKinesins and Cancer / _cedited by Frank Kozielski, FSB.
250			_a1st ed. _b2015.
260			_aLondon : _bill. ; _cc2015.
300			_ax, 271 p. : _bill. (some col.) ; _c24 cm.
505	0		_aPreface -- The kinesin superfamily -- The discovery and development of Eg5 inhibitors for the clinic -- Mechanism of action of Eg5 inhibitors -- Clinical trials of mitotic kinesin inhibitors -- Kif15; a useful target for anti-cancer therapy?.- Down-regulating CENP-E activity: for better or for worse -- The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug target.-Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapy -- Chromokinesins in genome maintenance and cancer -- Kif14: a clinically relevant kinesin and potential target for cancer therapy -- Kinesin-8 members and their potential as biomarker or therapeutic target -- The kinesin-6 members MKLP1, MKLP2 and MPP -- Non-motor spindle proteins as cancer chemotherapy targets -- Inhibitors of mitotic kinesins for cancer treatment: consequences for neurons -- Index.
520			_aThis interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development. Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future. The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail.
650		0	_aCancer research. _932075
650		0	_aCell biology. _932076
650		0	_aMedicinal chemistry. _932077
650		0	_aOncology. _932078
650		0	_aProteins. _932079
650	1	4	_aCancer Research. _932080
650	2	4	_aCell Biology. _932081
650	2	4	_aMedicinal Chemistry. _932082
650	2	4	_aOncology. _932078
650	2	4	_aProtein-Ligand Interactions. _932083
700	1		_aKozielski, FSB, Frank. _eeditor. _932084
776	0	8	_iPrint version: _tKinesins and cancer _z9789401797313 _w(DLC) 2015932649
776	0	8	_iPrinted edition: _z9789401797313
776	0	8	_iPrinted edition: _z9789401797337
776	0	8	_iPrinted edition: _z9789402403657
906			_a0 _bibc _corigres _du _encip _f20 _gy-gencatlg
942			_2ddc _cBKS
999			_c67490 _d67490